Cited by 548Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsVirus-based gene therapy research

Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer

Open access
Bernardes de Jesus, Bruno, Vera, Elsa, Schneeberger, Kerstin, Tejera, Agueda M., Ayuso, Eduard, Bosch, Fatima, Blasco, Maria A.·2012·EMBO Molecular Medicine

Abstract

A major goal in aging research is to improve health during aging. In the case of mice, genetic manipulations that shorten or lengthen telomeres result, respectively, in decreased or increased longevity. Based on this, we have tested the effects of a telomerase gene therapy in adult (1 year of age) and old (2 years of age) mice. Treatment of 1- and 2-year old mice with an adeno associated virus (AAV) of wide tropism expressing mouse TERT had remarkable beneficial effects on health and fitness, including insulin sensitivity, osteoporosis, neuromuscular coordination and several molecular biomarkers of aging. Importantly, telomerase-treated mice did not develop more cancer than their control littermates, suggesting that the known tumorigenic activity of telomerase is severely decreased when expressed in adult or old organisms using AAV vectors. Finally, telomerase-treated mice, both at 1-year and at 2-year of age, had an increase in median lifespan of 24 and 13%, respectively. These beneficial effects were not observed with a catalytically inactive TERT, demonstrating that they require telomerase activity. Together, these results constitute a proof-of-principle of a role of TERT in delaying physiological aging and extending longevity in normal mice through a telomerase-based treatment, and demonstrate the feasibility of anti-aging gene therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/emmm.201200245

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Systemic delivery of Tert lowers several senescence markers and ageing-related conditions and extends lifespan in wild-type mice, showing that telomeric DDR activation contributes to natural ageing.

    “Systemic delivery of Tert reduces several senescence markers and ageing-related conditions and extends the lifespan of wild-type mice, thus demonstrating that telomeric DDR activation plays a role in natural ageing263.”

    From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [263]

    The Results and Discussion report reduced p16 in most tissues, improved age-related health measures, and longer lifespan after AAV9-mTERT treatment of normal mice. The Discussion also links telomere-derived DNA damage to ageing, but the passages do not establish the more specific claim that activation of the telomeric DNA-damage response (DDR) contributes to natural ageing. Page numbers were not provided in our copy. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Control AAV9 expressing GFP at the same dose used (2e12 vg/mouse) does not alter median lifespan when administered to 2-year-old mice.

    “a previous report has demonstrated that control AAV9 expressing GFP at the same dose we used (2e12vg/mouse) does not alter median lifespan when administered to 2-year-old mice (Bernardes de Jesus et al., 2012)”

    From Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice (2024) · cites this paper as Bernardes de Jesus et al., 2012

    The Methods (Mice) and Results (AAV9-mediated expression) confirm that 2-year-old mice received control AAV9-GFP at 2 × 10¹² viral genomes per mouse. The Results (TERT-based gene therapy and longevity) compare lifespan in GFP-treated and untreated controls with TERT-treated mice, but do not report a direct median-lifespan comparison between GFP-treated and untreated mice. Thus, the assertion that GFP does not alter median lifespan is not established by our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bernardes de Jesus, B., Vera, E., Schneeberger, K., Tejera, A. M., Ayuso, E., Bosch, F., & Blasco, M. A.
Affiliations
  • Spanish National Cancer Research Centre (ES)
  • Universitat Autònoma de Barcelona (ES)
Venue
EMBO Molecular Medicine
Published
2012-05-15
Volume
4
Issue
8
Pages
691-704
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2169621456
Cited by
548
References
79
Citations by year
2026: 34 · 2025: 43 · 2024: 53 · 2023: 47 · 2022: 38 · 2021: 54 · 2020: 30 · 2019: 41 · 2018: 32 · 2017: 44 · 2016: 31 · 2015: 31 · 2014: 24 · 2013: 25 · 2012: 19
FWCI
21.23
Type
journal article
Language
en
Open access
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Funded Access
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
telomerase, telomerase reverse transcriptase, gene therapy, aging, longevity, anti-aging, adeno-associated virus vectors, telomere length, cancer risk, insulin sensitivity, osteoporosis, neuromuscular coordination, aging biomarkers
MeSH terms
Dependovirus, Aging, Animals, Female, Genetic Vectors, Longevity, Male, Neoplasms, Genetic Therapy, Telomerase, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review